Clinical Trial Update: Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating phenylbutyrate, dexamethasone, and sargramostim for refractory or relapsed acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Phenylbutyrate (phenylbutyrate)
• sargramostim (sargramostim)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Leukemia | Phase 2 | Status: COMPLETED